Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.

@article{Deguchi2008SuppressionOI,
  title={Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.},
  author={Masashi Deguchi and J. Kishino and M. Hattori and Y. Furue and M. Yamamoto and Izumi Mochizuki and Motofumi Iguchi and Y. Hirano and Kanji Hojou and M. Nagira and Y. Nishitani and Ken-ichi Okazaki and K. Yasui and A. Arimura},
  journal={European journal of pharmacology},
  year={2008},
  volume={601 1-3},
  pages={
          163-70
        }
}
  • Masashi Deguchi, J. Kishino, +11 authors A. Arimura
  • Published 2008
  • Chemistry, Medicine
  • European journal of pharmacology
  • We discovered a novel dihydroorotate dehydrogenase (DHO-DH) inhibitor, S-2678 ([2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy) pyridin-3-yl] biphenyl-4-yl]-(3-methyl-2-butenyl) amine). Its inhibitory activity against DHO-DH was more potent than that of A77 1726, an active metabolite of the anti-rheumatic drug leflunomide. S-2678 suppressed immunoglobulin production in mouse B cells and human peripheral blood mononuclear cells in vitro, with little or no inhibition of cell proliferation… CONTINUE READING
    5 Citations
    Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.
    • 137
    RSC_IB_C2IB20204B 1..21
    • PDF
    Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication
    • X. Wang, Xue Xu, +5 authors L. Yang
    • Biology, Medicine
    • Integrative biology : quantitative biosciences from nano to macro
    • 2013
    • 52
    • PDF
    Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.
    • L. McLean, Ying Zhang, +7 authors Y. Li
    • Chemistry, Medicine
    • Bioorganic & medicinal chemistry letters
    • 2010
    • 13
    Class 1 Oxidoreductases
    • 2

    References

    SHOWING 1-10 OF 22 REFERENCES
    Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
    • 113
    • Highly Influential
    Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound (*)
    • 193
    • PDF
    Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans*
    • 225
    • PDF
    In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
    • 71
    The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
    • 200
    Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
    • 222
    Regulation of B cell function by the immunosuppressive agent leflunomide.
    • 156
    Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
    • 206